Dendreon is a biotechnology company that developed PROVENGE, the first FDA-approved immunotherapy for metastatic castrate-resistant prostate cancer, using a patient's own immune cells. With manufacturing facilities in California and Georgia and a nationwide commercial team, Dendreon fosters a culture of putting patients first, integrity, trust, continuous improvement, and accountability.